The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
- 142 Downloads
Levodopa (L-DOPA), the gold standard treatment for Parkinson’s disease (PD), eventually causes L-DOPA-induced dyskinesia (LID) in up to 80% of patients. In the 6-hydroxydopamine (6-OHDA) rat model of PD, L-DOPA induces a similar phenomenon, which has been termed abnormal involuntary movement (AIM). We previously demonstrated that BMY-14802 suppresses AIM expression in this model.
Although BMY-14802 is widely used as a sigma-1 antagonist, it is also an agonist at serotonin (5-HT) 1A and adrenergic α-1 receptors. The current study was conducted to determine which of these mechanisms underlies BMY-14802’s AIM-suppressing effect. This characterization included testing the 5-HT1A agonist buspirone and multiple sigma agents. When these studies implicated a 5-HT1A mechanism, we subsequently undertook a pharmacological reversal study, evaluating whether the 5-HT1A antagonist WAY-100635 counteracted BMY-14802’s AIM-suppressing effects.
Buspirone dose-dependently suppressed AIM, supporting past findings. However, no AIM-suppressing effects were produced by drugs with effects at sigma receptors, including BD-1047, finasteride, SM-21, DTG, trans-dehydroandrosterone (DHEA), carbetapentane, and opipramol. Finally, we show for the first time that the AIM-suppressing effect of BMY-14802 was dose-dependently prevented by WAY-100635 but not by the α-1 antagonist prazosin.
BMY-14802 exerts its AIM-suppressing effects via a 5-HT1A agonist mechanism, similar to buspirone. Other 5-HT1A agonists have failed clinical trials, possibly due to submicromolar affinity at other receptors, including D2, which may exacerbate PD symptoms. BMY-14802 is a promising candidate for clinical trials due to its extremely low affinity for the D2 receptor and lack of extrapyramidal effects during prior clinical trials for schizophrenia.
KeywordsBMY-14802 Buspirone 5-HT1A 6-hydroxydopamine L-DOPA-induced dyskinesia Parkinson’s disease Rat Sigma
Conflict of interest
No conflicts of interest are present.
- Abou-Gharbia M, Moyer JA, Patel U, Webb M, Schiehser G, Andree T, Haskins JT (1989) Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1, 2-benzisothiazol-3-one 1, 1-dioxides and thiadiazinones: potential anxiolytic agents. J Med Chem 32:1024–1033PubMedCrossRefGoogle Scholar
- Bevilacqua M, Vago T, Monopoli A, Baldi G, Forlani A, Antona C, Biglioli P, Scrofani R, Norbiato G (1991) Alpha 1 adrenoceptor subtype mediates noradrenaline induced contraction of the human internal mammary artery: radioligand and functional studies. Cardiovasc Res 25:290–294PubMedCrossRefGoogle Scholar
- Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C (2008) Effects of coincident 5-HT(1A) receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl.) 199:99–108CrossRefGoogle Scholar
- Ghelardini C, Galeotti N, Gualtieri F, Bellucci C, Manetti D, Giotti A, Malmberg-Aiello P, Galli A, Bartolini A (1997) Antinociceptive profile of 3-alpha-tropanyl 2-(4-Cl-phenoxy) butyrate (SM-21) [corrected]: a novel analgesic with a presynaptic cholinergic mechanism of action. J Pharmacol Exp Ther 282:430–439PubMedGoogle Scholar
- Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P (2006) In 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1A agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319:1225–1234PubMedCrossRefGoogle Scholar
- Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346–1353PubMedCrossRefGoogle Scholar
- Perrone R, Berardi F, Colabufo NA, Tortorella V, Fiorentini F, Olgiati V, Vanotti E, Govoni S (1994) Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1, 2-dihydronaphthalen-4-yl)-n-propyl]piperazines 1. Synthesis and structure-activity relationships. J Med Chem 37:99–104PubMedCrossRefGoogle Scholar
- Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP (2004) Sigma(1) receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) 75:68–75Google Scholar
- Yevich JP, New JS, Lobeck WG, Dextraze P, Bernstein E, Taylor DP, Yocca FD, Eison MS, Temple DL Jr (1992) Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents. J Med Chem 35:4516–4525PubMedCrossRefGoogle Scholar